Assetmark Inc. Acquires 16,299 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Assetmark Inc. raised its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 18.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 102,436 shares of the biopharmaceutical company’s stock after acquiring an additional 16,299 shares during the period. Assetmark Inc.’s holdings in Catalyst Pharmaceuticals were worth $2,536,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Deerfield Management Company L.P. boosted its position in shares of Catalyst Pharmaceuticals by 72.8% during the third quarter. Deerfield Management Company L.P. now owns 4,974,767 shares of the biopharmaceutical company’s stock worth $98,003,000 after purchasing an additional 2,095,291 shares in the last quarter. Janus Henderson Group PLC raised its stake in Catalyst Pharmaceuticals by 200.6% during the 4th quarter. Janus Henderson Group PLC now owns 1,719,767 shares of the biopharmaceutical company’s stock worth $40,124,000 after buying an additional 1,147,565 shares during the period. Morgan Stanley lifted its holdings in Catalyst Pharmaceuticals by 59.1% during the fourth quarter. Morgan Stanley now owns 2,933,399 shares of the biopharmaceutical company’s stock worth $68,466,000 after acquiring an additional 1,089,775 shares in the last quarter. Glenmede Investment Management LP grew its stake in Catalyst Pharmaceuticals by 781.8% in the third quarter. Glenmede Investment Management LP now owns 680,224 shares of the biopharmaceutical company’s stock valued at $13,400,000 after acquiring an additional 603,084 shares during the period. Finally, Bank of America Corp DE increased its holdings in shares of Catalyst Pharmaceuticals by 30.6% in the second quarter. Bank of America Corp DE now owns 2,365,675 shares of the biopharmaceutical company’s stock worth $51,335,000 after acquiring an additional 554,200 shares in the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $31.49 on Friday. The stock has a market capitalization of $3.86 billion, a PE ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74. Catalyst Pharmaceuticals, Inc. has a 1-year low of $19.05 and a 1-year high of $32.56. The firm has a fifty day simple moving average of $31.38 and a 200 day simple moving average of $27.27.

Analysts Set New Price Targets

Several brokerages recently issued reports on CPRX. Robert W. Baird lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 7th. Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Citigroup cut Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $35.00 to $31.50 in a report on Friday, May 8th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Friday, March 27th. Finally, Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Catalyst Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).